Megasoft (MEGASOFT) | Financial Analysis & Statements
Megasoft Ltd. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2025Income Metrics
Revenue
0
Gross Profit
0
Operating Income
-29.0M
Net Income
5.6M
EPS (Diluted)
₹0.08
Balance Sheet Metrics
Total Assets
3.0B
Total Liabilities
242.0M
Shareholders Equity
2.8B
Debt to Equity
0.09
Cash Flow Metrics
Revenue & Profitability Trend
Megasoft Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 19.7M | 524.0M | 594.0M |
| Cost of Goods Sold | 0 | 19.8M | 38.6M | 321.4M | 320.3M |
| Gross Profit | 0 | -19.8M | -18.9M | 202.5M | 273.7M |
| Gross Margin % | 0.0% | 0.0% | -96.0% | 38.7% | 46.1% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 54.9M | 39.6M | 88.5M | 131.7M | 98.1M |
| Other Operating Expenses | 18.7M | 28.2M | 45.7M | 94.3M | 111.5M |
| Total Operating Expenses | 73.6M | 67.8M | 134.2M | 226.0M | 209.5M |
| Operating Income | -145.2M | -121.1M | -184.1M | -71.0M | 17.8M |
| Operating Margin % | 0.0% | 0.0% | -933.8% | -13.5% | 3.0% |
| Non-Operating Items | |||||
| Interest Income | 35.5M | 29.2M | 41.8M | 1.2M | 1.8M |
| Interest Expense | 181.9M | 169.3M | 100.6M | 21.3M | 46.0M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 84.5M | 82.2M | 113.7M | 52.4M | 18.5M |
| Income Tax | 0 | 6.4M | 0 | 6.2M | -26.0K |
| Effective Tax Rate % | 0.0% | 7.7% | 0.0% | 11.8% | -0.1% |
| Net Income | -299.4M | -127.5M | 88.3M | 46.2M | 18.5M |
| Net Margin % | 0.0% | 0.0% | 448.0% | 8.8% | 3.1% |
| Key Metrics | |||||
| EBITDA | 311.0M | 283.4M | 253.9M | 220.6M | 110.8M |
| EPS (Basic) | ₹-4.06 | ₹-1.73 | ₹1.20 | ₹0.74 | ₹0.35 |
| EPS (Diluted) | ₹-4.06 | ₹-1.73 | ₹1.20 | ₹0.74 | ₹0.35 |
| Basic Shares Outstanding | 73770041 | 73770041 | 73770041 | 62858066 | 52529163 |
| Diluted Shares Outstanding | 73770041 | 73770041 | 73770041 | 62858066 | 52529163 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Megasoft Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 91.7M | 170.5M | 22.9M | 352.4M | 67.7M |
| Short-term Investments | 3.8M | 14.4M | 67.0M | 19.9M | 4.5M |
| Accounts Receivable | 0 | 0 | 0 | 227.1M | 311.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 208.6M | 77.0M | 89.9M | 38.0M | 150.4M |
| Total Current Assets | 560.3M | 532.2M | 539.1M | 806.1M | 673.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 2.0B | 0 | 0 | 0 | 0 |
| Goodwill | - | - | 0 | 351.7M | 1.6B |
| Intangible Assets | - | - | - | - | 46.2M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 168.2M | 50.0M | 50.0M | 1.1M | 1.6M |
| Total Non-Current Assets | 3.1B | 3.1B | 3.2B | 2.1B | 2.5B |
| Total Assets | 3.6B | 3.7B | 3.8B | 2.9B | 3.2B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 0 | 10.8M | 2.5M | 189.0M | 94.4M |
| Short-term Debt | 90.3M | 97.1M | 77.5M | 20.9M | 304.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 9.3M | 12.8M | 11.4M | 12.8M | 5.2M |
| Total Current Liabilities | 683.1M | 259.0M | 234.0M | 536.8M | 1.5B |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.3B | 1.4B | 1.4B | 269.4M | 40.3M |
| Deferred Tax Liabilities | - | - | 0 | 41.0K | 0 |
| Other Non-Current Liabilities | 7.1M | 16.4M | 22.3M | 33.8M | 12.5M |
| Total Non-Current Liabilities | 1.5B | 1.6B | 1.6B | 479.6M | 210.7M |
| Total Liabilities | 2.2B | 1.9B | 1.8B | 1.0B | 1.8B |
| Equity | |||||
| Common Stock | 737.7M | 737.7M | 737.7M | 737.7M | 442.7M |
| Retained Earnings | 348.5M | 647.9M | 775.4M | 686.8M | 862.8M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.4B | 1.8B | 1.9B | 1.8B | 1.4B |
| Key Metrics | |||||
| Total Debt | 1.4B | 1.5B | 1.5B | 290.3M | 344.6M |
| Working Capital | -122.8M | 273.3M | 305.1M | 269.3M | -873.1M |
Balance Sheet Composition
Megasoft Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -299.4M | -121.1M | 88.3M | 52.4M | 18.5M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -340.0M | 162.5M | 175.3M | -58.0M | 182.3M |
| Operating Cash Flow | -492.1M | 183.0M | 321.2M | -27.3M | 243.2M |
| Investing Activities | |||||
| Capital Expenditures | -172.7M | -111.9M | 165.3M | -11.5M | -33.3M |
| Acquisitions | - | 0 | 10.0M | 0 | - |
| Investment Purchases | - | 0 | -1.4B | -15.2M | - |
| Investment Sales | - | 0 | 55.0M | 0 | - |
| Investing Cash Flow | -172.7M | -111.9M | -1.2B | -26.7M | -33.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | -101.4M |
| Financing Cash Flow | 1.0K | - | -180.2M | 295.0M | -102.6M |
| Free Cash Flow | 194.7M | 305.3M | 136.8M | 153.2M | 165.3M |
| Net Change in Cash | -664.7M | 71.1M | -1.0B | 241.0M | 107.3M |
Cash Flow Trend
Megasoft Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
7.91
Price to Book
4.71
Price to Sales
195.06
PEG Ratio
-0.07
Profitability Ratios
Profit Margin
80.76%
Operating Margin
-1,366.82%
Return on Equity
64.13%
Return on Assets
26.26%
Financial Health
Current Ratio
8.39
Debt to Equity
1.39
Beta
0.94
Per Share Data
EPS (TTM)
₹23.90
Book Value per Share
₹40.12
Revenue per Share
₹23.14
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MEGASOFT | 301.2B | 7.91 | 4.71 | 64.13% | 80.76% | 1.39 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Torrent | 1.4T | 61.35 | 16.50 | 25.18% | 17.83% | 33.40 |
| Dr. Reddy's | 1.1T | 19.40 | 2.94 | 16.10% | 16.36% | 18.03 |
| Lupin | 1.1T | 22.74 | 5.37 | 18.98% | 17.76% | 31.51 |
Financial data is updated regularly. All figures are in the company's reporting currency.





